Ashland To Expand Hydroxypropylcellulose Capacity - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Ashland To Expand Hydroxypropylcellulose Capacity


Ashland Specialty Ingredients, a commercial unit of Ashland Inc., announced plans to significantly expand production capacity of its Klucel hydroxypropylcellulose (HPC) product line in Hopewell, Virginia. The expansion is expected to begin production in the second half of 2016. Klucel HPC is a tablet binder and coating ingredient used in pharmaceutical applications and dietary supplements worldwide.

Ashland opened a pharmaceutical center of excellence in Hyderabad, India, earlier this year, and is expanding its technical capabilities in Wilmington, Del. and its Polyplasdone crospovidone capacity in Texas City, Texas.

Source: Ashland

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here